DE3632201C2 - Pharmazeutische Zusammensetzung mit retardierter Freisetzung des Wirkstoffes - Google Patents
Pharmazeutische Zusammensetzung mit retardierter Freisetzung des WirkstoffesInfo
- Publication number
- DE3632201C2 DE3632201C2 DE3632201A DE3632201A DE3632201C2 DE 3632201 C2 DE3632201 C2 DE 3632201C2 DE 3632201 A DE3632201 A DE 3632201A DE 3632201 A DE3632201 A DE 3632201A DE 3632201 C2 DE3632201 C2 DE 3632201C2
- Authority
- DE
- Germany
- Prior art keywords
- composition according
- isradipine
- cellulose
- fatty material
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 239000012730 sustained-release form Substances 0.000 title claims description 5
- 238000013268 sustained release Methods 0.000 title claims description 4
- 239000013543 active substance Substances 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims description 39
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 claims description 24
- 229960004427 isradipine Drugs 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 229920002678 cellulose Polymers 0.000 claims description 10
- 239000001913 cellulose Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 claims description 8
- 229940074979 cetyl palmitate Drugs 0.000 claims description 8
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 claims description 8
- -1 2,1,3-benzoxadiazol-4-yl Chemical group 0.000 claims description 7
- 239000000416 hydrocolloid Substances 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 238000002844 melting Methods 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- QERUYFVNIOLCHV-UHFFFAOYSA-N darodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC2=NON=C12 QERUYFVNIOLCHV-UHFFFAOYSA-N 0.000 description 10
- 229950009702 darodipine Drugs 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 229910052681 coesite Inorganic materials 0.000 description 4
- 229910052906 cristobalite Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229910052682 stishovite Inorganic materials 0.000 description 4
- 229910052905 tridymite Inorganic materials 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 235000021152 breakfast Nutrition 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 125000005908 glyceryl ester group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical class CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 1
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 1
- KMBQOSGPHMRPBA-UHFFFAOYSA-N 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid Chemical class OC(=O)C1=C(C)NC(C)=C(C(O)=O)C1C1=CC=CC2=NON=C12 KMBQOSGPHMRPBA-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- GWVCGGYBZZFNAG-UHFFFAOYSA-N CC1=C(C(C(=C(N1C)C)C(=O)O)(C2=CC=CC3=NON=C32)C(C)C)C(=O)O Chemical compound CC1=C(C(C(=C(N1C)C)C(=O)O)(C2=CC=CC3=NON=C32)C(C)C)C(=O)O GWVCGGYBZZFNAG-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920003095 Methocel™ K15M Polymers 0.000 description 1
- 241000428199 Mustelinae Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB858524135A GB8524135D0 (en) | 1985-10-01 | 1985-10-01 | Darodipine compositions |
| GB858524653A GB8524653D0 (en) | 1985-10-07 | 1985-10-07 | Pharmaceutical formulations |
| GB858531419A GB8531419D0 (en) | 1985-12-20 | 1985-12-20 | Pindolol compositions |
| GB868603097A GB8603097D0 (en) | 1986-02-07 | 1986-02-07 | Pharmaceutical formulations |
| GB868605037A GB8605037D0 (en) | 1986-02-28 | 1986-02-28 | Oral pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3632201A1 DE3632201A1 (de) | 1987-04-02 |
| DE3632201C2 true DE3632201C2 (de) | 1997-05-07 |
Family
ID=27516617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3632201A Expired - Lifetime DE3632201C2 (de) | 1985-10-01 | 1986-09-23 | Pharmazeutische Zusammensetzung mit retardierter Freisetzung des Wirkstoffes |
Country Status (20)
| Country | Link |
|---|---|
| KR (1) | KR920008817B1 (enExample) |
| AT (1) | AT402257B (enExample) |
| BE (1) | BE905516A (enExample) |
| CA (1) | CA1298784C (enExample) |
| CH (1) | CH669524A5 (enExample) |
| DE (1) | DE3632201C2 (enExample) |
| DK (1) | DK170016B1 (enExample) |
| ES (1) | ES2002508A6 (enExample) |
| FR (1) | FR2589732B1 (enExample) |
| GR (1) | GR862457B (enExample) |
| HK (1) | HK392A (enExample) |
| HU (1) | HU197201B (enExample) |
| IE (1) | IE59589B1 (enExample) |
| IL (1) | IL80182A (enExample) |
| LU (1) | LU86615A1 (enExample) |
| NL (1) | NL194822C (enExample) |
| NZ (1) | NZ217732A (enExample) |
| PT (1) | PT83456B (enExample) |
| SE (1) | SE503222C2 (enExample) |
| SG (1) | SG103391G (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440457B1 (en) | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
| WO2003065970A2 (en) * | 2001-02-20 | 2003-08-14 | Royal College Of Surgeons Ie | Treatment of fibromyalgia and related fatigue syndromes using pindolol |
| TW200616681A (en) * | 2004-10-05 | 2006-06-01 | Recordati Ireland Ltd | Lercanidipine capsules |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH630257A5 (en) * | 1975-03-17 | 1982-06-15 | Hoffmann La Roche | Sustained release formulation |
| CH639659A5 (de) * | 1978-12-18 | 1983-11-30 | Sandoz Ag | Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung. |
| DD145004A3 (de) * | 1978-09-25 | 1980-11-19 | Reinhard Huettenrauch | Verfahren zur herstellung fester a zneiformen |
| CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| JPS6056122B2 (ja) * | 1980-05-21 | 1985-12-09 | 塩野義製薬株式会社 | 徐放性製剤 |
| GB2084017B (en) * | 1980-09-18 | 1984-08-22 | Sandoz Ltd | Pharmaceutical compositions effective against coronary heat disease and hypertension |
| US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| CA1208558A (en) * | 1982-10-07 | 1986-07-29 | Kazuo Kigasawa | Soft buccal |
| GB2154874B (en) * | 1984-02-29 | 1987-11-04 | Sandoz Ltd | Bromoscriptine compositions |
| JPS61501511A (ja) * | 1984-03-21 | 1986-07-24 | アメリカン・ホ−ム・プロダクツ・コ−ポレイション | 徐放性医薬カプセル |
| JPS6124516A (ja) * | 1984-07-12 | 1986-02-03 | Fujisawa Pharmaceut Co Ltd | 持続性錠剤 |
-
1986
- 1986-09-19 NL NL8602370A patent/NL194822C/nl not_active IP Right Cessation
- 1986-09-19 HU HU864004A patent/HU197201B/hu unknown
- 1986-09-22 CH CH3780/86A patent/CH669524A5/de not_active IP Right Cessation
- 1986-09-23 DE DE3632201A patent/DE3632201C2/de not_active Expired - Lifetime
- 1986-09-29 IL IL80182A patent/IL80182A/xx not_active IP Right Cessation
- 1986-09-29 KR KR1019860008136A patent/KR920008817B1/ko not_active Expired
- 1986-09-29 IE IE256586A patent/IE59589B1/en not_active IP Right Cessation
- 1986-09-29 DK DK464686A patent/DK170016B1/da not_active IP Right Cessation
- 1986-09-29 NZ NZ217732A patent/NZ217732A/xx unknown
- 1986-09-29 SE SE8604112A patent/SE503222C2/sv not_active IP Right Cessation
- 1986-09-29 PT PT83456A patent/PT83456B/pt unknown
- 1986-09-29 CA CA000519302A patent/CA1298784C/en not_active Expired - Lifetime
- 1986-09-29 GR GR862457A patent/GR862457B/el unknown
- 1986-09-30 BE BE1/011554A patent/BE905516A/fr not_active IP Right Cessation
- 1986-09-30 AT AT0260486A patent/AT402257B/de not_active IP Right Cessation
- 1986-09-30 ES ES8602313A patent/ES2002508A6/es not_active Expired
- 1986-09-30 LU LU86615A patent/LU86615A1/fr unknown
- 1986-10-01 FR FR868613668A patent/FR2589732B1/fr not_active Expired
-
1991
- 1991-12-04 SG SG1033/91A patent/SG103391G/en unknown
-
1992
- 1992-01-02 HK HK3/92A patent/HK392A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AT402257B (de) | 1997-03-25 |
| HUT44701A (en) | 1988-04-28 |
| IL80182A0 (en) | 1986-12-31 |
| DE3632201A1 (de) | 1987-04-02 |
| KR870003777A (ko) | 1987-05-04 |
| IL80182A (en) | 1991-01-31 |
| IE59589B1 (en) | 1994-03-09 |
| SG103391G (en) | 1992-01-17 |
| DK170016B1 (da) | 1995-05-01 |
| LU86615A1 (fr) | 1987-04-02 |
| GR862457B (en) | 1987-01-29 |
| CA1298784C (en) | 1992-04-14 |
| NL194822C (nl) | 2003-04-03 |
| DK464686D0 (da) | 1986-09-29 |
| SE8604112L (sv) | 1987-04-02 |
| ATA260486A (de) | 1996-08-15 |
| HU197201B (en) | 1989-03-28 |
| ES2002508A6 (es) | 1988-08-16 |
| IE862565L (en) | 1987-04-01 |
| NZ217732A (en) | 1990-07-26 |
| PT83456A (en) | 1986-10-01 |
| DK464686A (da) | 1987-04-02 |
| PT83456B (pt) | 1989-05-12 |
| SE8604112D0 (sv) | 1986-09-29 |
| NL194822B (nl) | 2002-12-02 |
| FR2589732A1 (fr) | 1987-05-15 |
| NL8602370A (nl) | 1987-05-04 |
| HK392A (en) | 1992-01-10 |
| KR920008817B1 (ko) | 1992-10-09 |
| SE503222C2 (sv) | 1996-04-22 |
| FR2589732B1 (fr) | 1989-07-13 |
| CH669524A5 (enExample) | 1989-03-31 |
| BE905516A (fr) | 1987-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69922964T2 (de) | Ranolazinhaltige arzneimittel mit verzögerter wirkstoffabgabe | |
| DE69201793T2 (de) | Mehrschichtige zubereitung mit kontrollierter freisetzung. | |
| DE69802543T3 (de) | Verbesserte multipartikel-tablette mit schnellauflösbarkeit | |
| DE69215612T2 (de) | Verzögerte Freigabe-Matrix für Arzneimittel | |
| DE3152519C2 (de) | Neues Fenofibrat-Fertigpr{parat mit verz¦gerter Wirkstofffreisetzung | |
| DE3689983T2 (de) | Arzneimittel mit langsamer Wirkstofffreisetzung. | |
| DE3520184C2 (de) | Neue galenische Retardform | |
| DE69721833T2 (de) | Verwendung von sibutramine analogen zur senkung des fettspiegels | |
| DE3719818C2 (de) | Pharmazeutische Zusammensetzung | |
| DE4122039A1 (de) | Orale feste pharmazeutische dosierungsform mit programmierter freisetzung | |
| EP0265848A1 (de) | Arzneizubereitungen zur oralen Verabreichung, die als Einzeldosis 10 bis 240 mg Dihydropyridin enthalten | |
| DE69815856T2 (de) | Cefadroxilmonohydrat tablettenformulierung | |
| DE69805433T2 (de) | Tiagabin enthaltende spheroide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel | |
| DE69420776T2 (de) | Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer | |
| EP0313535B1 (en) | Oral formulation of buspirone and salts thereof | |
| EP0208144A1 (de) | Ambroxol oder bromhexin enthaltendes arzneimittelgranulat | |
| CH667592A5 (de) | 9,10-dihydrogenierte ergotalkaloide enthaltende pharmazeutische zusammensetzungen. | |
| DE2950154C2 (enExample) | ||
| AT402257B (de) | Verfahren zur herstellung von pharmazeutischen zusammensetzungen mit kontrollierter freisetzung eines 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro- 2,6-dimethyl-3,5-pyridindicarboxylatester- wirkstoffes | |
| DE69914472T2 (de) | Levosimendanhaltige oral anzuwendende arzneimittel mit gesteuerter wirkstoffverabreichung | |
| DE3505743C2 (de) | Bromocriptin enthaltende Zusammensetzungen | |
| DE60312642T2 (de) | Pharmazeutische zusammensetzung mit modifizierter freisetzung | |
| EP0315197B1 (de) | Oral anzuwendende Arzneiform zur einmal täglichen Behandlung der Hypertonie mit Diltiazemhydrochlorid | |
| DE69532176T3 (de) | Desogestrel enthaltende Tablette, Kapsel oder Granulat und Verfahren zu deren Herstellung | |
| DD216383A5 (de) | Verfahren zur herstellung eines analgetischen paeracetamolpraeparates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: NOVARTIS AG, BASEL, CH |
|
| 8328 | Change in the person/name/address of the agent |
Free format text: SPOTT WEINMILLER & PARTNER, 80336 MUENCHEN |